498
Participants
Start Date
August 15, 2014
Primary Completion Date
January 11, 2016
Study Completion Date
January 10, 2024
Daratumumab
Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
VELCADE (Bortezomib)
VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
Dexamethasone
Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Birmingham
Los Angeles
Stamford
Jacksonville
Atlanta
Niles
Topeka
Westwood
Marrero
Boston
Lansing
New York
Chapel Hill
Portland
Philadelphia
Providence
Seattle
Adelaide
Concord
Fitzroy
Hobart
Melbourne
Nedlands
Woodville South
Barretos
Porto Alegre
Salvador
São Paulo
Brno
Hradec Králové
Ostrava-Poruba
Prague
Bamberg
Berlin
Düsseldorf
Freiburg im Breisgau
Göttingen
Hamburg
Mainz
München
Stuttgart
Tübingen
Ulm
Würzburg
Budapest
Debrecen
Győr
Pécs
Veszprém
Huixquilucan
Monterrey
Alkmaar
Amersfoort
Dordrecht
Groningen
Leiden
Maastricht
Nijmegen
The Hague
Chorzów
Katowice
Krakow
Poznan
Warsaw
Krasnodar
Moscow
Nizhny Novgorod
Penza
Pyatigorsk
Ryazan
Samara
Sochi
Syktyvkar
Busan
Hwasun
Seoul
Suwon
Ulsan
Madrid
Salamanca
San Sebastián de los Reyes
Toledo
Valencia
Linköping
Luleå
Lund
Örebro
Sundsvall
Umeå
Uppsala
Västerås
Ankara
Istanbul
Izmir
Kayseri
Kocaeli
Malatya
Cherkasy
Dnipro
Ivano-Frankivsk
Kiev
Lviv
Poltava
Vinnitsa
Zaporizhzhya
Janssen Research & Development, LLC
INDUSTRY